Atrial Fibrillation Algorithms Clinical Validation Study
NCT ID: NCT04699812
Last Updated: 2022-08-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
573 participants
INTERVENTIONAL
2020-11-16
2021-12-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Watch Atrial Fibrillation (AF) Detection Investigation
NCT04074434
Electrocardiogram Clinical Validation Study
NCT04842123
Validation Study of Pulse Wave Velocity and Augmentation Index in Atrial Fibrillation
NCT02754349
Effect of taVNS on Heart Rate in Persistent Atrial Fibrillation
NCT05944575
Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
NCT01505296
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COHORT 1
This will include subjects with no known history of AF
ELECTROCARDIOGRAM (ECG) PATCH WEAR
ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
COHORT 2
This will include subjects with no known history of aF, but with history of frequent premature atrial contractions (PACs), frequent premature ventricular contractions (PVCs), supraventricular tachycardia (SVT), or non-sustained ventricular tachycardia (NSVT)
ELECTROCARDIOGRAM (ECG) PATCH WEAR
ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
COHORT 3
This will include subjects with known history of paroxysmal, persistent, or chronic AF
ELECTROCARDIOGRAM (ECG) PATCH WEAR
ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
COHORT 4
Will include subjects with permanent AF
ELECTROCARDIOGRAM (ECG) PATCH WEAR
ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELECTROCARDIOGRAM (ECG) PATCH WEAR
ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing and able to participate in the study procedures as described in the consent form
3. Be 22 years of age and older
4. Able to communicate effectively with and follow instructions from the study staff
5. Able to wear the wrist device for duration of study participation
6. For Cohort 1, have no known medical history of AF
7. For Cohort 2, have no known medical history of AF and active diagnosis of at least one of the following arrhythmias within the past 2 years:
1. Frequent PACs, defined as at least 1% of total beats of atrial ectopic beats by 24-48 hour Holter, ambulatory ECG monitor, or implantable loop recorder)
2. Frequent PVCs, defined as at least 1% of total beats of ventricular ectopic beats by 24-48 hour Holter, ambulatory ECG monitor, or implantable loop recorder
3. SVT, which will include atrial tachycardia, atrioventricular nodal re-entrant tachycardia, atrioventricular re-entrant tachycardia by 12-lead ECG or 24-48 hour Holter, ambulatory ECG monitor, or implantable loop recorder
4. NSVT, defined as three or more consecutive ventricular beats at a rate of at least 100 beats per minute and lasting no more than 30 seconds, by 12-lead ECG or 24-48 hour Holter, ambulatory ECG monitor, or implantable loop recorder
8. For Cohorts 3 and 4, have a known diagnosis of AF at the time of screening (confirmed by electronic medical record (EMR) or self-report) and have had a recent episode of AF, or confirmed AF on ECG, in the past 12 months
9. For Cohort 4, have a known diagnosis of permanent AF at the time of screening (confirmed by EMR or self-report) and have had a recent episode of AF, or confirmed AF on ECG, in the past 12 months
10. Meet additional binning based on demographics.
Exclusion Criteria
2. Mental impairment resulting in limited ability to cooperate
3. Known uncontrolled medical conditions, such as (but not limited to) significant anemia, important electrolyte imbalance and untreated or uncontrolled thyroid disease
4. Open wound(s) on the wrist and/or forearm
5. Tattoos, large moles, or scars on the wrist at the wrist device location
6. Skin conditions on either wrist that would preclude subject from wearing a wristband on either wrist
7. Known allergy or sensitivity to medical adhesives, isopropyl alcohol, wristbands, or ECG patch
8. Medical history or physical assessment finding that makes the subject inappropriate for participation according to investigator(s)
9. Participation in a previous study that used a wrist-worn sensor device with a simultaneous ECG reference patch
10. Implantable cardiac devices such as a Pacemaker or Implantable Cardioverter Defibrillator
11. Clinically significant hand tremors, as judged by the investigator
12. Acute illness including COVID and other respiratory illnesses
13. Subjects with known history of AF on rhythm control medications with history of complete AF rhythm control (i.e history of zero AF burden) will be excluded from Cohorts 3 and 4
22 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iqvia Pty Ltd
INDUSTRY
Apple Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Tsay, MD, PhD
Role: STUDY_DIRECTOR
Apple Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research of South Florida
Coral Gables, Florida, United States
American Health Network of Indiana Llc
Avon, Indiana, United States
Heartland Cardiology Webb
Wichita, Kansas, United States
Healtheast
Saint Paul, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
099-25141
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.